Treatment options in Waldenström's macroglobulinaemia: The role of the purine analogues

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 6, 2001, Pages 945-952

  Owen, R G ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Claribine; Fludarabine; Waldenst ms macroglobulinaemia

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE; CARMUSTINE; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DRUG METABOLITE; FLUDARABINE PHOSPHATE; MELPHALAN; MITOXANTRONE; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISOLONE; PURINE DERIVATIVE; RITUXIMAB; VIDARABINE; VINCRISTINE;

B LYMPHOCYTE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MEDICAL DOCUMENTATION; PLASMAPHERESIS; REVIEW; WALDENSTROEM MACROGLOBULINEMIA;

ALKYLATING AGENTS; ANTIMETABOLITES; CHLORAMBUCIL; CLADRIBINE; CLINICAL TRIALS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GUIDELINES; HUMANS; MIDDLE AGED; PENTOSTATIN; PLASMAPHERESIS; PURINE NUCLEOSIDES; QUALITY OF LIFE; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 0034878998     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.6.945     Document Type: Review

References (68)

1. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia - A new syndrome?
2. Waldenström's macroglobulinemia: Clinical features, complications, and management
3. Waldenström's macroglobulinaemia: Laboratory diagnosis and treatment
4. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
5. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid tissues: Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997
6. Waldenström's macroglobulinemia
7. Incidence of Waldenström's macroglobulinemia
8. Waldenström's macroglobulinemia: Development of diagnostic criteria and identification of prognostic factors
9. Prognostic factors in Waldenström's macroglobulinemia: A report of 167 cases
10. Study of prognosis in Waldenström's macroglobulinemia: A proposal for a simple binary classification with clinical and investigational utility
11. Prognostic factors in Waldenström macroglobulinemia: A report on 232 patients with the description of a new scoring system and its validation on 253 other patients
12. Primary systemic amyloidosis: A rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia
13. Autoimmune thrombocytopenia in Waldenström's macroglobulinemia
14. Waldenström's macroglobulinemia and peripheral neuropathy: A clinical and immunologic study of 25 patients
15. Plasma cell dyscrasia and peripheral neuropathy: Identification of the myelin antigens that react with human paraproteins
16. Bone marrow histology in Waldenström's macroglobulinemia
17. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma
18. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes
19. Clinicopathological correlates of IgM paraproteinemias
20. The spectrum of IgM monoclonal gammopathy in 430 cases
21. Plasmapheresis for hyperviscosity syndrome in Waldenström's macroglobulinemia and multiple myeloma: Influence on blood rheology and the microcirculation
22. Association between plasma viscosity and all cause mortality. Results from the MONICA-Augsburg cohort follow-up study 1984-1992
23. Primary macroglobulinemia. Review with a report on thirty-one cases and notes on the value of continuous chlorambucil therapy
24. Macroglobulinemia: An analysis for forty patients
25. Waldenström's macroglobulinemia: A prospective study comparing daily versus intermittent oral chlorambucil
26. Waldenström's macroglobulinemia with increased serum IgG levels treated with low doses of cyclophosphamide
27. Waldenström's macroglobulinemia: Results of a combined oral treatment in 34 newly diagnosed patients
28. Waldenström's macroglobulinaemia: Long term results with the M2 protocol
29. Results of a multicentric randomized study comparing the efficacy of cyclophosphamide, doxorubicin and prednisone (CAP) to that of fludarabine (FAMP) in patients with Waldenström's macroglobulinemia (WM) in first primary refractory disease
30. Nucleoside analogs: Cellular pharmacology, mechanisms of action, and strategies for combination therapy
31. Clinical trials of the purine analogs in chronic lymphocytic leukemia
32. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
33. The French Cooperative Group on CLL: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced stage chronic lymphocytic leukaemia
34. Pharmacokinetic study of single low doses of oral fludarabine phosphate in patients with 'low grade' non-Hodgkin's Lymphoma and B-cell chronic lymphocytic leukemia
35. Fludarabine therapy in macroglobulinemic lymphoma
36. Fludarabine therapy in Waldenström's macroglobulinemia
37. Fludarabine treatment in resistant Waldenström's macroglobulinaemia
38. Activity of fludarabine in previously-treated Waldenström's macroglobulinemia: A report of 71 cases
39. Multicenter Phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia and mantle-cell lymphoma
40. Phase II intergroup trial of fludarabine (FAMP) in Waldenström's macroglobulinemia (WM): Results of the Southwest Oncology Group trial (SWOG 9003) in 220 patients
41. Serum beta 2 microglobulin and IgM identify distinct prognostic subsets in patients with Waldenström's macroglobulinemia (WM)
42. Cold agglutinin hemolysis responding to fludarabine therapy
43. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: A Phase II randomized study
44. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: Report of a prospective, randomized, multicenter trial
45. Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine
46. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine
47. 2-Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine
48. Cladribine for Waldenström's macroglobulinaemia
49. Treatment of Waldenström's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors
50. First-line treatment of Waldenström's disease with cladribine
51. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia
52. Bolus administration of cladribine in the treatment of Waldenström's macroglobulinaemia
53. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia
54. Clinical development of 2′-deoxycoformycin
55. Response of Waldenström's macroglobulinaemia to pentostatin
56. Rituximab therapy in Waldenström's macroglobulinemia: Preliminary evidence of clinical activity
57. European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma and small β-cell lymphocytic lymphoma
58. Phenotypic and clinical evidence supports rituximab for Waldenström's macroglobulinemia
59. Prospective evaluation of rituximab for the treatment of Waldenström's macroglobulinemia
60. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
61. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas
62. Remission induction in patients with lymphoid malignancies using unconjugated campath-1 monoclonal antibodies
63. Expression of CD52 in human hematopoietic malignancies
64. Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody campath-1H
65. Campath-1H monoclonal antibody therapy for previously treated low-grade non-Hodgkin's lymphomas: A Phase II multicenter study
66. High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia
67. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström's macroglobulinaemia
68. Allogeneic bone marrow transplantation for advanced Waldenström's macroglobulinemia